The Follicular Lymphoma International Prognostic Index (FLIPI) is widely used for risk stratification of patients with follicular lymphoma (FL). Motivated by evolvement in treatment modalities, several prognostic models for FL have been proposed recently.

This systematic review aimed to identify available prognostic models for newly diagnosed FL and discuss their potential limitations. A total of ten studies fulfilled the inclusion criteria. Different clinical, laboratory, radiological, and histopathological findings were combined in prognostic models. The majority of studies developed models from clinical trial cohorts, and most lacked validation in populations treated with current treatment options.

Although the FLIPI is the most widely used model for prognostication in FL patients, current prognostic models, including FLIPI, are rarely used in clinical practice for treatment decision-making. Future studies should validate the existing, or develop new prognostic models, to identify which of the current standard treatment options benefit high-risk FL patients the most.

滤泡性淋巴瘤国际预后指数 (FLIPI) 广泛用于滤泡性淋巴瘤 (FL) 患者的风险分层。受治疗方式发展的推动，最近提出了几种 FL 预后模型。

本系统评价旨在为新诊断的 FL 确定可用的预后模型并讨论它们的潜在局限性。共有 10 项研究符合纳入标准。在预后模型中结合了不同的临床、实验室、放射学和组织病理学发现。大多数研究从临床试验队列中开发了模型，并且大多数研究缺乏在接受当前治疗方案治疗的人群中的验证。

尽管 FLIPI 是最广泛用于 FL 患者预后的模型，但当前的预后模型（包括 FLIPI）很少用于临床实践中的治疗决策。未来的研究应该验证现有的，或开发新的预后模型，以确定当前的标准治疗方案中哪些最有利于高危 FL 患者。